SAN FRANCISCO, CA—Transcatheter mitral valve replacement (TMVR) with the novel Sapien M3 device (Edwards Lifesciences) is associated with low rates of adverse clinical outcomes and sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results